



December 10-14, 2019

Henry B. Gonzalez Convention Center, San Antonio, Texas, USA



## WELCOME TO SAN ANTONIO AND THE 2019 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)

UT Health Cancer Center, Baylor College of Medicine, and the American Association for Cancer Research (AACR) take great pride in presenting this year's SABCS. We are incredibly excited to have you attend.

The San Antonio Breast Cancer Symposium is the premiere international breast cancer symposium. We hope you will take advantage of every opportunity to expand your knowledge by attending a variety of sessions and networking with the field's leading professionals. This Symposium is translational and strives to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.

The Breast Cancer Symposium format incorporates diverse elements in order to provide maximum scientific exposure and interaction. These elements include plenary lectures, oral abstract presentations, general poster sessions, general spotlight poster discussion sessions, workshops, educational sessions, award lectures, debate, panel and case discussions, selected mini-symposia, basic science, translational, and clinical forums, and a year in review over a 5 day period.

The meeting begins on Tuesday with the Educational Sessions which are an update on advances in the technologies available for translational research. These sessions are to provide people with a better understanding of the talks they hear using the techniques described. They also provide researchers with a guide to the techniques they should be considering for their studies. In general, meeting days begin with poster discussion sessions and a poster session/continental breakfast at 7:00 AM and end with poster discussion sessions and a poster session/reception that concludes at 7:00 PM. Most sessions are consecutive which allows participants to attend all translational sessions. Specific basic science research and clinical research sessions, the educational sessions, poster discussion/poster sessions, and the case discussion/basic science and clinical forums are presented as parallel sessions

With so many valuable sessions it is hard to attend everything you want. Don't worry, within 24 hours of a presentation, posters and oral presentations including slides will be made available online at [www.sabcs.org](http://www.sabcs.org).

We are extremely grateful to the Program Planning, Abstract Review, and Abstract Selection Committees for their exceptional work this year in putting together an amazing program featuring prominent speakers from around the world. We urge you to take full advantage of everything the meeting has to offer.

On behalf of the executive committee, we hope you enjoy your week in San Antonio. If there is anything we can do for you, please do not hesitate to ask.

Sincerely,

Kent Osborne, MD

Carlos Arteaga, MD

Virginia Kaklamani, MD

## ISSUE 1 AT A GLANCE

- 1 Welcome
- 2 SABCS Mobile App  
Plenary Lecture Schedule
- 3 Product Theatre Schedule  
Special Appreciation  
Grants
- 4-5 Scholarship Recipients
- 6-7 Award Recipients  
Exhibitors
- 8 Supporters




### WiFi Access

#### HOW TO CONNECT:

- 1: In your wireless settings scan for available wireless networks.
- 2: Open your favorite browser.
- 3: When symposium welcome page loads you are connected!

## Download the SAN ANTONIO BREAST CANCER SYMPOSIUM MOBILE APP



- Stay organized with up-to-the-minute Exhibitor, Speaker, and Event information
- Sync the app across all of your devices with Multi-Device Sync
- Receive important real-time communications from the SABCS
- Build a personalized schedule and bookmark exhibitors
- Take notes and download event handouts and presentations
- Interactively locate sessions and exhibitors on the Henry B. Gonzalez Convention Center maps
- Find attendees and connect with your colleagues through Friends
- Stay in-the-know and join in on social media with #SABCS19
- And much, much more!

### DOWNLOADING IS EASY!

#### SEARCH:

The App Store or Google Play for "SABCS"



#### SCAN:



Also available at:

[www.core-apps.com/dl/sabcs2019](http://www.core-apps.com/dl/sabcs2019)

### PLENARY LECTURE 1: STROMAL CELLS AND MATRIX REMODELING AS ESSENTIAL REGULATORS OF THE TUMOR MICROENVIRONMENT

Ellen Puré, PhD, University of Pennsylvania, Philadelphia, PA

HALL 3, 8:15 AM - 8:45 AM

Ellen Puré, PhD, will discuss how fibroblast activation protein (FAP)-expressing cells and the extracellular matrix regulate tumor and adipose cell behavior in her plenary lecture, "Stromal Cells and Matrix Remodeling as Essential Regulators of the Tumor Microenvironment," Puré, from the University of Pennsylvania, will present at the Symposium on Wednesday morning.

Several studies show that the initiation, progression, and metastasis is associated with desmoplasia, which is characterized by activation of mesenchymal-derived stromal cells and dynamic remodeling of the extracellular matrix. The stromal cell component has subpopulations of cancer-associated fibroblasts (CAFs) and CAF-mediated pathways that regulate tumor progression. Puré plans to focus on the fibroblast activation protein (FAP)-expressing CAFs, which promote tumor progression and are correlated with poorer survival in breast and multiple other cancers.

Preclinical studies showed reductions in tumorigenesis, progression, and metastases in FAP-knockout mouse models of lung, colon, pancreatic, and breast cancer generated using genetic, chimeric antigen receptor (CAR) T cell, or antibody-targeting approaches. Puré and her colleagues also found, unexpectedly, that their FAP-null mouse model became obese following consumption of a high-fat diet, but the obesity was a "healthy" obesity, according to Puré, and not associated with the high-risk, aggressive disease commonly demonstrated in obesity-associated breast cancer.

"Obesity and [FAP] play a role in modifying connective tissue in a way that allows fat cells to expand...without causing things like insulin resistance associated with 'risky' obesity," said Puré.

Although Puré noted that she and her colleagues plan to pursue the development of a FAP-targeted CAR T cell for clinical use in the future, she said that evaluating the mechanisms of FAP on tumor and adipose cells to identify molecular pathways involved will be the focus of her lecture.

"We got into breast cancer because we wanted to understand the interface between [tumor] microenvironment and environmental factors," said Puré. "We know there are risk factors [for breast cancer], but what we don't know is [whether] those effects act directly on the tumor cell, through changes in the microenvironment, or through changes in immunity. We have to step back and look at it at a broader level before tackling it clinically."

Puré predicted that future research on FAP and other components of the stromal cells and extracellular matrix will be instrumental in guiding development of therapies.

"We are learning a lot more about how the connective tissue response to environmental factors puts a tissue at risk for allowing a tumor cell, if it transforms, to survive and grow and eventually promote its metastasis," said Puré. "Stromal cells and [extracellular] matrix are going to provide a whole plethora of targets that can be used in combination with immune modulators and targeted therapies."

### PRODUCT THEATRE SCHEDULE EXHIBIT HALL 2

WEDNESDAY, DECEMBER 11

12:30 PM

Integrating Clinical-Pathologic Features with the Recurrence Score® Result to Help Guide Adjuvant Treatment Decisions  
*Presented by Genomic Health, Inc*

2:00 PM

HER2-Positive Early Breast Cancer: Optimizing adjuvant treatment based on response to neoadjuvant therapy  
*Presented by Genentech, A Member of the Roche Group*

THURSDAY, DECEMBER 12

11:00 AM

New Survival Data for a Treatment Option Approved for Patients With HR+, HER2- Metastatic Breast Cancer  
© Lilly USA, LLC 2019. All rights reserved. *Presented by Lilly Oncology*

12:30 PM

Innovative Oral Treatment Options for Patients: HR+/HER2- MBC or gBRCA-Mutated TNBC and HR+/HER2- MBC  
*Presented by Pfizer Oncology*

2:00 PM

Lynparza: An Optimal Targeted Treatment for gBRCAm HER2-Negative Metastatic Breast Cancer  
*Presented by AstraZeneca*

3:30 PM

Advancing the Treatment of TECENTRIQ, the first cancer immunotherapy approved for the treatment of PD-L1 mTNBC  
*Presented by Genentech, A Member of the Roche Group*

FRIDAY, DECEMBER 13

11:00 AM

Innovative Biomarker Strategies for Translational Medicine and Clinical Practice in Breast Cancer.  
*Presented by NanoString Technologies*

12:30 PM

The ONLY Endocrine Biomarker: Presenting New Pivotal Data from the Translational aTTom  
*Presented by Biotheranostics, Inc*

2:00 PM

Two Considerations in HR+/HER2- mBC: The Importance of PIK3CA Mutations and the Arrival of OS Data With a CDK4/6 Inhibitor  
*Presented by Novartis Oncology*

## SPECIAL APPRECIATION

SABCS gratefully acknowledges the Breast Cancer Research Foundation for generous support of the AACR Outstanding Investigator Award for Breast Cancer Research and the Susan G. Komen Foundation for their support of the Educational Sessions.



SABCS recognizes and thanks the American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) for their collaboration regarding radiation oncology and surgical content presented at the 2019 SABCS.



## GRANTS

Funding for this conference was made possible (in part) by 5R13CA213939-04 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the US Government.

This activity is supported by educational grants provided by AstraZeneca, Merck, Pfizer, Daiichi Sankyo, Eisai, Novartis, and Lilly (for further information concerning Lilly grant funding, visit [www.lillygrantoffice.com](http://www.lillygrantoffice.com)).

## SABCS 2019 SCHOLARSHIP RECIPIENTS

### SABCS Basic Science Scholar Award Recipients

For laboratory-based investigators-in-training whose work focuses on the biology of breast cancer and preclinical models of its development and progression.

- B2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells  
*Hemn Mohammadpour, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY*  
P3-01-02 Thursday, December 12 5:00 PM
- A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment  
*Ofir Cohen, PhD, Dana-Farber Cancer Institute, Boston, MA*  
GS2-02 Wednesday, December 10 3:30 PM
- Single-cell analysis of breast cancer metastasis using patient-derived xenograft model reveals clonal relationship between primary tumor and its metastases  
*Hakwoo Lee, University of British Columbia, Vancouver, Canada*  
GS6-05 Friday, December 13 4:15 PM
- Risk of radiation induced secondary malignancies in gBRCA carriers following breast cancer therapy  
*Shir Schlosser, Tel Aviv University, Tel Aviv, Israel*  
PD6-04 Thursday, December 12 5:00 PM
- Molecular signatures of DCIS to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study  
*Aatish Thennavan, University of North Carolina, Chapel Hill, NC*  
PD6-09 Thursday, December 12 5:00 PM

### SABCS Clinical Scholar Award Recipients

For clinical scientists-in-training who are actively pursuing clinical or clinical/translational research in breast cancer.

- Clinico-pathological and molecular features in young women with metastatic breast cancer  
*Kristen Carroll, Northwestern University, Robert H. Lurie Comprehensive Cancer Center*  
PD8-03 Thursday, December 12 5:00 PM
- The impact of breast cancer treatment concordance on survival in relation to comorbidity burden  
*Melissa Edwards, MB ChB, University of Auckland, New Zealand*  
P3-08-02 Thursday, December 12 5:00 PM
- Comparison of 4 techniques of clinical breast examination: A cross-sectional diagnostic test evaluation  
*Kush Lohani, MD, All India Institute of Medical Sciences, New Delhi, India*  
P2-02-01 Thursday, December 12 7:00 AM
- Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane  
*Veronica Mariotti, MD, Moffitt Cancer Center, Tampa, FL*  
PDI-04 Wednesday, December 11 5:00 PM
- Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer  
*Natsuko Onishi, MD, PhD, University of California San Francisco, San Francisco, CA*  
PD9-05 Friday, December 13 5:00 PM

### Arti Hurria Travel Award Recipients

Created in memory of Dr. Arti Hurria and in recognition of her commitment to the mentorship and training of the next generation of geriatric oncologists. For geriatric oncologists-in-training.

- Use of systemic therapy for early stage breast cancer in older adults: results from the Bridging the Age Gap study  
*Nicolò Matteo Luca Battisti, MD, PhD, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom*  
P2-14-08 Thursday, December 12 7:00 AM
- Delayed initiation of adjuvant chemotherapy in older women with breast cancer  
*Demetria Smith-Graziani, MD, UT MD Anderson Cancer Center, Houston, TX*  
P2-14-04 Thursday, December 12 7:00 AM

### Coltman Scholar Award Recipients

In memory of Dr. Charles A. Coltman, co-founder of SABCS, to commemorate the significant contributions he made to oncology medicine. For clinical scientists-in-training.

- Impact of increased mammary adiposity on DCIS progression  
*Mathilde Almekinders, MD, Netherlands Cancer Institute, Amsterdam, Netherlands*  
P6-15-07 Saturday, December 14 7:00 AM
- Fragility index of trials supporting approval of breast cancer drugs  
*Alexandra Desnoyers, MD, Princess Margaret Cancer Center, Toronto, Canada*  
P4-15-01 Friday, December 13 7:00 AM
- Genomic profiling of primary and metastatic breast cancer in men  
*Joshua Drago, MD, Memorial Sloan Kettering Cancer Center, New York, NY*  
P4-17-01 Friday, December 13 7:00 AM
- Breast cancer risk thresholds as a predictor of chemoprevention uptake in the Athena Breast Health Network  
*Yash Huilgol, University of California San Francisco, San Francisco, CA*  
P5-08-01 Friday, December 13 5:00 PM
- Impact of ER-positivity on time and pattern of relapse in early-stage breast cancer patients  
*Nathalie LeVasseur, MD, BC Cancer, Vancouver, Canada*  
P3-08-04 Thursday, December 12 5:00 PM

### AACR Associate Member Award Recipients

For presenters of meritorious abstracts who are Associate Members of the American Association for Cancer Research (AACR).

- Breast cancer arising on the left side is biologically more aggressive and has worse outcomes compared to the right side  
*Yara Abdou, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY*  
P2-09-09 Thursday, December 12 7:00 AM
- Development and characterization of a first-in-class small molecule inhibitor of PELP1  
*Kristin Altwegg, MS, UT Health San Antonio, San Antonio, TX*  
P3-10-01 Thursday, December 12 5:00 PM
- A dual role of natural killer cells in breast cancer metastasis  
*Isaac Chan, MD, PhD, Johns Hopkins University, Baltimore, MD*  
P3-01-01 Thursday, December 12 5:00 PM
- Polygenic risk stratification among women carrying moderate penetrance pathogenic variants in breast cancer predisposition genes: Results from the CARRIERS study  
*Chi Gao, MS, Harvard T.H. Chan School of Public Health, Boston, MA*  
PD3-02 Wednesday, December 11 5:00 PM
- Liquid biopsy methods and machine learning modeling to understand organ tropism and metastatization behavior of metastatic breast cancer  
*Lorenzo Gerrata, MD, Northwestern University, Chicago, IL*  
P3-01-05 Thursday, December 12 5:00 PM
- Assessment of intratumoral heterogeneity in early stage estrogen receptor (ER) positive breast cancer  
*Sofia Mastoraki, PhD, UT MD Anderson Cancer Center, Houston, TX*  
P4-06-03 Friday, December 13 7:00 AM
- Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial  
*Rosalyn Sayaman, PhD, City of Hope, Duarte, CA*  
P1-21-08 Wednesday, December 11 5:00 PM
- Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance  
*Alberto Servetto, MD, UT Southwestern Medical Center, Dallas, TX*  
PD7-04 Thursday, December 12 5:00 PM
- A novel model to study to metaplastic TNBC  
*Vrutant Shah, PhD, UT MD Anderson Cancer Center, Houston, TX*  
P1-03-01 Wednesday, December 11 5:00 PM
- Comparison of recommendations for germline genetic testing in an unselected cohort of patients with breast cancer  
*Siddhartha Yadav, MD, Mayo Clinic, Rochester, MN*  
P6-08-01 Saturday, December 14 7:00 AM



**SABCS 2019 AWARD RECIPIENTS**

**WILLIAM L. MCGUIRE MEMORIAL LECTURE**

The McGuire Award was established in 1992 to honor William L. McGuire, MD, who co-founded the San Antonio Breast Cancer Symposium® in 1977 along with Charles A. Coltman, MD.

**What Would Bill Think?**

Wednesday, December 11<sup>th</sup> 11:15 AM - Hall 3

Dr. Joseph Sparano, associate director for clinical research at the Montefiore Einstein Center for Cancer Care, Albert Einstein Cancer Center, New York, is being recognized for a distinguished career marked by his leadership, collaboration, and practice-changing achievements. His work in clinical and translational breast cancer research has improved the lives of numerous patients.

He has played a key role in the design and implementation of numerous clinical trials since joining the ECOG-ACRIN Cancer Research Group (formerly the Eastern Cooperative Oncology Group or ECOG) in 1991. He served as study chair for the recently reported TAILORx trial. This National Cancer Institute-



**RECIPIENT:**  
**Joseph Sparano, MD**  
Montefiore Medical Center  
Bronx, NY

sponsored, multi-center trial enrolled more than 10,000 women with early-stage breast cancer. The results of the TAILORx trial led to modification of National Comprehensive Cancer Network (NCCN) guidelines, immediately changing clinical practice.

Dr. Sparano's research on biomarkers of recurrence and prognosis has moved the field forward and led to more effective, personalized treatments for cancer patients. His peers extol his organizational skills and he is recognized as a committed mentor. In 2001 he initiated the ECOG Young Investigator Symposium, now an annual event that has provided the opportunity for more than 200 young clinicians to interact with senior investigators and learn about cooperative group research.

**SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE**

**Deciphering Stem and Progenitor Cells to Understand Breast Cancer**

Wednesday, December 11<sup>th</sup> 2:15 PM - Hall 3

The Brinker Award for Scientific Distinction in Basic Science will be presented to Jane Visvader, PhD, and Geoffrey Lindeman, MBBS, FRACP, PhD, Joint Heads of the Cancer Biology and Stem Cells Division at the Walter and Eliza Hall Institute (WEHI), in Melbourne, Australia. Drs. Visvader and Lindeman have made significant contributions to our understanding of how normal and cancerous cells develop in the breast. Their research has resulted in critical insights about the regulation of normal breast cell growth and breast cancer initiation and progression, including the identification of breast stem cells that give rise to normal breast tissue and the breast cells that are predisposed to becoming cancerous in women with BRCA1 gene mutations."



**CO-RECIPIENT:**  
**Jane Visvader, PhD**  
The Walter and Eliza Hall Institute (WEHI)  
Melbourne, Australia




**CO-RECIPIENT:**  
**Geoffrey Lindeman, MBBS, FRACP, PhD**  
The Walter and Eliza Hall Institute (WEHI)  
Melbourne, Australia

**SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH**

**The Molecular Etiology of Luminal-Type Breast Cancer**

Wednesday, December 11<sup>th</sup> 2:45 PM - Hall 3

The Brinker Award for Scientific Distinction in Clinical Research will be presented to Matthew J. Ellis, MB BChir, BSc, PhD, FRCP, Professor of Medicine and Cellular and Molecular Biology, Director of the Lester and Sue Smith Breast Center, and Associate Director for Translational Research at the Dan L Duncan Cancer Center, Baylor College of Medicine. Dr. Ellis is being honored for seminal contributions in understanding the genomics of breast cancer and translating this knowledge to the clinic to improve the efficacy of breast cancer treatment. His work to define the



**RECIPIENT:**  
**Matthew J. Ellis, MB BChir, BSc, PhD, FRCP**  
Baylor College of Medicine  
Houston, TX

genomic landscape of breast cancer, drug resistance mechanisms, and biomarkers for breast cancer prognosis, coupled with his pioneering research in the pre-surgical treatment of breast cancer, has resulted in significant advances that are paving the way for more personalized treatments for breast cancer.

**EXHIBITORS**

- |  |                                     |  |
|--|-------------------------------------|--|
| Agendia, Inc   | Global Breast Cancer Conference     | Pfizer Oncology - Ibrance & Talzena        |
| Alamo Breast Cancer Foundation   | Harborside                          | Philips Molecular Pathway DX               |
| Ambry Genetics, A Konica Minolta Company                               | HealthCare Partners Nevada          | Physician's Education Resource, LLC        |
| American Association for Cancer Research                               | Hologic, Inc                        | PreludeDx                                  |
| Amgen, Inc   | The IBC Network Foundation          | Puma Biotechnology, Inc.                   |
| AstraZeneca  | Immunomedics, Inc                   | Radius Health, Inc.                        |
| Athenex Oncology   | Integrated Oncology                 | Roche Diagnostics Corporation              |
| Biotheranostics, Inc.  | Invivo                              | R-Pharm US                                 |
| Breast Cancer Art Exhibit  | Invitae                             | Research To Practice                       |
| BRAVE Coalition Foundation   | JAMA Network                        | Seattle Genetics                           |
| Breast Cancer Action   | Jeunesse Innovations                | Sema4                                      |
| Bristol-Myers Squibb   | Lilly Oncology                      | Sermonix Pharmaceuticals                   |
| Caris Life Sciences  | Lumicell, Inc                       | Sibliotech, Inc.                           |
| Celgene Corporation  | MacroGenics, Inc                    | Society of Surgical Oncology               |
| Cianna Medical/Merit Medical   | Male Breast Cancer Coalition        | Spectrum Pharmaceuticals                   |
| Coherus BioSciences  | Med-Care Pharmaceuticals            | Stayhealthy Inc.                           |
| Daiichi Sankyo, Inc.   | Medscape Oncology                   | Syndax Pharmaceuticals                     |
| Dan L. Duncan Comprehensive Cancer Center @ Baylor College of Medicine | Menarini Silicon Biosystems         | Tactile Medical                            |
| Datar Cancer Genetics Limited  | Merck & Co., Inc                    | Tempus                                     |
| Dignitana  | METAvivor Research and Support, Inc | TerSera Therapeutics                       |
| Eisai, Inc   | MpBC Global Alliance, Inc           | TRIO - Translational Research in Oncology  |
| Elsevier   | Mylan Inc                           | TxSCO - Texas Society of Clinical Oncology |
| Elucent Medical, Inc   | Myriad Genetic Laboratories, Inc.   | UT MD Anderson Cancer Center               |
| Encore Medical Education, LLC.   | NanoString Technologies             | VISION RT                                  |
| Epic Sciences  | NeoGenomics                         | Wolters Kluwer                             |
| ESMO - European Society For Medical Oncology                           | Novartis Oncology                   | Zero Gravity                               |
| Genentech, A Member of the Roche Group                                 | OBI Pharma USA, Inc                 | Zeiss                                      |
| Genomic Health   | The Oncologist                      |  |
|  | Paxman USA Inc                      |  |
|  | Pfizer                              |  |
|  | Pfizer Oncology Medical             |  |

**2019 FOUNDATION, INDUSTRY, & AGENCY SUPPORT\***

We are proud to acknowledge the following for their contributions to and generous support of our program.

**PREMIER**



**ANGEL**



Biotheranostics, Inc

**PATRON**  
Bristol-Myers Squibb  
NanoString Technologies

Seattle Genetics

**MAJOR SUPPORTERS**

Amgen, Inc  
Athenex Oncology  
Immunomedics

MacroGenics, Inc  
Myriad Genetic Laboratories, Inc  
The Oncologist

Puma Biotechnology, Inc  
Radius Health

**CONTRIBUTORS**

Agendia, Inc  
Alamo Breast Cancer Foundation  
American Association for Cancer  
Research  
Baylor College of Medicine

Caris Life Sciences  
Celgene Corporation  
Encore Medical Education, LLC  
Epic Sciences  
Sema4

Spectrum Pharmaceuticals  
Stayhealthy Inc  
Syndax Pharmaceuticals  
Wolters Kluwer

**DONORS**

Ambry Genetics, A Konica Minolta  
Company  
BRAVE Coalition Foundation  
Breast Cancer Action  
Cianna Medical/Merit Medical  
Coherus BioSciences, Inc  
Datar Cancer Genetics Limited  
Dignitana  
Elucent Medical, Inc  
ESMO - European Society for Medical  
Oncology  
Global Breast Cancer Conference  
HealthCare Partners Nevada

Hologic, Inc  
The IBC Network Foundation  
Integrated Oncology  
Invicro  
JAMA Network  
Lumicell, Inc  
Male Breast Cancer Coalition  
Medscape Oncology  
Menarini Silicon Biosystems  
NeoGenomics  
OBI Pharma USA, Inc  
Paxman USA Inc.  
Philips Molecular Pathway DX

Prelude Dx  
R-Pharm US  
Research To Practice  
Roche Diagnostics Corporation  
Sibliotech, Inc  
Tempus  
TerSera Therapeutics  
TRIO - Translational Research in  
Oncology  
UT MD Anderson Cancer Center  
Zero Gravity  
Zeiss

\*AT PRESS TIME